A synthetic analog of growth hormone-releasing hormone (GHRH 1-29) previously FDA-approved for diagnosing and treating growth hormone deficiency in children.
The Journal of endocrinology|1995|Giustina A et al.
The aim of our study was to investigate the effect of hexarelin, a novel GH-releasing peptide-6 analog, and GH-releasing hormone (GHRH) (alone or in combination) on GH secretion in adult patients with increased somatostatin tone due to chronic glucoc…
Randomized Controlled Trial
PMID: 7561633
Journal of the National Cancer Institute|1995|Pinski J et al.
BACKGROUND: Insulin-like growth factor I (IGF-I) may be involved in the proliferation of human osteosarcomas. Most of the IGF-I found in blood is produced in the liver, where transcription of the IGF-I gene is regulated by growth hormone (GH). Recent…
Animal StudyIn Vitro
PMID: 7473836
Metabolism: clinical and experimental|1995|Giustina A et al.
The aim of the study was to elucidate the role of the neuropeptide galanin in the regulation of somatotropic and gonadotropic function in normal women. Thirteen normally ovulating (aged 28 to 40 years), non-obese (body mass index, 18.4 to 27.1 kg/m2)…
Randomized Controlled TrialAnimal Study
PMID: 7543651
Clinical endocrinology|1995|Ramirez G et al.
OBJECTIVE: Individuals adapted to high altitude (HA) have abnormalities in endocrine function and specifically in the pituitary-thyroid axis and aldosterone regulation. In this study we assessed hypothalamic-pituitary function in men adapted to high…
PMID: 7641401
International journal of peptide and protein research|1995|Felix A, Lu Y, Campbell R
Conditions have been developed for the site-specific pegylation (NH2-terminus, side-chain and carboxy-terminus) of a potent analog of growth hormone-releasing factor, [Ala15]-hGRF(1-29)-NH2. These pegylated peptides were prepared by solid-phase pepti…
Animal StudyIn Vitro
PMID: 8537179
Acta paediatrica (Oslo, Norway : 1992)|1995|Grunt J et al.
Seven children with significant idiopathic short stature (SISS) whose heights were significantly below the third percentile (SD score for height -2.5 to -3.5) and who had normal levels of growth hormone (GH) were treated with growth hormone releasing…
PMID: 7670244
Journal of neuroimmunology|1995|Delgado M et al.
In the present study, the effects of PACAP27, PACAP38 and VIP in a concentration range from 10(-13) to 10(-6) M were studied in vitro on the spontaneous and directed mobility of lymphocytes from rat spleen and thymus. The results show that VIP and bo…
Animal StudyIn Vitro
PMID: 7499501
Journal of endocrinological investigation|1995|Rico M et al.
In this work, the combined use of the morphometric study of somatotroph cells and plasma GH levels provided new data for the interpretation of the role played by OT and GHRH on GH cells. GHRH 1-29 (15 micrograms/kg), oxytocin (2.5 IU animal) or 1 ml…
PMID: 7594239
Journal of neurochemistry|1995|Yuwiler A, Brammer G, Bennett B
The 27 amino acid peptide, pituitary adenylate cyclase-activating polypeptide (PACAP-27), and its 38 amino acid analogue, PACAP-38, stimulate serotonin-N-acetyltransferase (NAT) activity and N-acetylserotonin (NAS) and melatonin content of pineal gla…
Animal Study
PMID: 7722512
Clinical endocrinology|1995|Hindmarsh P et al.
OBJECTIVE: Strategies to limit the final height of tall children have centred on the use of high doses of sex steroids to advance skeletal maturation. This limits therapy to the peripubertal years whereas the greatest gain in height is in the prepube…
Clinical Trial
PMID: 7621570
Proceedings of the National Academy of Sciences of the United States of America|1995|Horváth J, Groot K, Schally A
The release of growth hormone (GH) and cAMP was studied in superfused rat pituitary cells by infusing growth hormone-releasing hormone (GHRH) at different doses or a combination of GHRH and somatostatin 14 (SS-14). Three-minute pulses of GHRH caused…
Animal Study
PMID: 7892191
Journal of endocrinological investigation|1995|Looij B et al.
In man, GHRH has been shown to potentiate the TSH-releasing activity of TRH. To study the way by which GHRH affects TRH-stimulated TSH release, we examined the effect of GHRH (1-29)NH2 on basal and stimulated TSH secretion in intact male rats and sup…
Animal StudyIn Vitro
PMID: 7615907
The Journal of clinical endocrinology and metabolism|1995|Loche S et al.
Hexarelin (Hex) is a new synthetic hexapeptide with potent growth hormone (GH)-releasing activity in both animals and men. We evaluated the GH response to a maximal dose of Hex (2 micrograms/kg iv) and GH-releasing hormone (GHRH) (1-29, 1 microgram/k…
PMID: 7852535
Pediatric research|1995|Harel Z, Tannenbaum G
Protein malnutrition early in life stunts subsequent physical growth in both humans and rats, but the mechanism(s) is unknown. To test the hypothesis that temporary early life dietary protein restriction produces long-term alterations in the growth h…
Animal Study
PMID: 8552444
Inflammation research : official journal of the European Histamine Research Society ... [et al.]|1995|Estévez M et al.
Human growth releasing factor (GRF) (1-29)NH2 releases histamine from pleural and peritoneal rat mast cells by a non cytotoxic and non immunological mechanism. Pretreatment of cells with pertussis toxin markedly inhibits the secretion, suggesting a p…
Animal Study
PMID: 7544679
Biomedical peptides, proteins & nucleic acids : structure, synthesis & biological activity|1995|Wray V et al.
High quality PACAP-related peptide (PRP), a 29 amino-acid region of the PACAP precursor protein, has been synthesized in quantities sufficient for biological and structural studies. PRP has a distinct biological activity on the gallbladder that is si…
PMID: 9346858
Peptides|1995|Hassan H et al.
To study structure-activity relationships of growth hormone-releasing hormone (GHRH), a competitive binding assay was developed using cloned porcine adenopituitary GHRH receptors expressed in human kidney 293 cells. Specific binding of [His1, 125I-Ty…
Animal Study
PMID: 8745060
Metabolism: clinical and experimental|1995|Lee E et al.
Hyperthyroidism is associated with an impairment of growth hormone (GH) responses to secretagogues. The aim of this study was to evaluate the effect of acipimox, an antilipolytic agent able to decrease free fatty acids (FFA), on GH response to GH-rel…
Clinical Trial
PMID: 7476342
The Journal of clinical endocrinology and metabolism|1994|Giustina A et al.
The aim of our study was to elucidate the relationship between the level of circulating cortisol and the GH responsiveness to GHRH in six hypoadrenal patients (one male and five females; age range, 35-67 yr; body mass index range, 18-31 kg/m2). Twent…
Clinical Trial
PMID: 7962318
Neuropeptides|1994|Nowak M et al.
The effect of a subcutaneous bolus injection of 2 micrograms magnitude of Ac,Tyr1,D-Phe2-GRF(1-29) amide, a specific VIP antagonist (VIP-A), on the hypothalamo-pituitary-adrenocortical (HPA) axis were investigated in both normal and ether- or cold-st…
Animal Study
PMID: 7862261